- Home
- SVII vs CYBN Comparison
SVII vs CYBN Comparison
Compare SVII & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- CYBN
- Stock Information
- Founded
- SVII 2021
- CYBN 2019
- Country
- SVII United States
- CYBN Canada
- Employees
- SVII N/A
- CYBN N/A
- Industry
- SVII Blank Checks
- CYBN Pharmaceuticals and Biotechnology
- Sector
- SVII Finance
- CYBN Health Care
- Exchange
- SVII Nasdaq
- CYBN Nasdaq
- Market Cap
- SVII 119.4M
- CYBN 176.5M
- IPO Year
- SVII 2022
- CYBN N/A
- Fundamental
- Price
- SVII $12.19
- CYBN $6.00
- Analyst Decision
- SVII
- CYBN Strong Buy
- Analyst Count
- SVII 0
- CYBN 3
- Target Price
- SVII N/A
- CYBN $85.00
- AVG Volume (30 Days)
- SVII 23.5K
- CYBN 630.3K
- Earning Date
- SVII 01-01-0001
- CYBN 11-12-2025
- Dividend Yield
- SVII N/A
- CYBN N/A
- EPS Growth
- SVII N/A
- CYBN N/A
- EPS
- SVII 0.17
- CYBN N/A
- Revenue
- SVII N/A
- CYBN N/A
- Revenue This Year
- SVII N/A
- CYBN N/A
- Revenue Next Year
- SVII N/A
- CYBN N/A
- P/E Ratio
- SVII $72.64
- CYBN N/A
- Revenue Growth
- SVII N/A
- CYBN N/A
- 52 Week Low
- SVII $11.20
- CYBN $4.81
- 52 Week High
- SVII $12.74
- CYBN $13.88
- Technical
- Relative Strength Index (RSI)
- SVII 59.54
- CYBN 38.13
- Support Level
- SVII $12.04
- CYBN $6.16
- Resistance Level
- SVII $12.35
- CYBN $6.55
- Average True Range (ATR)
- SVII 0.10
- CYBN 0.48
- MACD
- SVII 0.00
- CYBN -0.06
- Stochastic Oscillator
- SVII 63.64
- CYBN 9.18
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.